原发骨弥漫大B细胞淋巴瘤的基因突变特征与GCB表型
该回顾性研究纳入103例骨内弥漫大B细胞淋巴瘤(含34例原发骨DLBCL),对比63例非骨性GCB型DLBCL。原发骨DLBCL以GCB表型为主,B2M、EZH2、IRF8、TNFRSF14突变显著更常见,且生存优于同期非骨性I/II期GCB型DLBCL。
要点
- 原发骨DLBCL以GCB表型为主,免疫组化74%、NanoString 88%。
- B2M、EZH2、IRF8、TNFRSF14突变在原发骨DLBCL中显著更常见。
- 原发骨DLBCL生存优于同期非骨性I/II期GCB型DLBCL。
核心结论
- 原发骨DLBCL具有GCB表型、中心细胞样基因表达谱及GCB相关突变谱,预后良好,可能为独立结外DLBCL实体。
研究设计与样本
- 回顾性研究纳入103例骨内DLBCL(含34例原发骨DLBCL),对比63例非骨性GCB型DLBCL。
- 细胞起源用免疫组化及NanoString/Lymph2Cx基因表达谱分析,突变谱用靶向二代深度测序检测52个B细胞淋巴瘤相关基因。
主要发现
- 骨内DLBCL(含原发骨DLBCL)免疫组化74%、NanoString 88%分类为GCB表型。
- 扩展NanoString/Lymph2Cx无监督层次聚类显示原发骨DLBCL与非骨性GCB型DLBCL基因表达谱聚类显著不同(P < .001)。
- 两个靶向基因表达面板的23个基因表达水平提示原发骨DLBCL为中心细胞样表型,非骨性GCB型DLBCL为中心母细胞样。
- 原发骨DLBCL中B2M、EZH2、IRF8、TNFRSF14突变频率显著高于非骨性GCB型DLBCL(P = .031、P = .010、P = .047、P = .003)。
- 原发骨DLBCL生存显著优于同期Ann Arbor I/II期非骨性GCB型DLBCL(P = .016)。
临床怎么用
- 原发骨DLBCL可按GCB表型及特征性突变谱识别,其良好预后可为治疗强度选择提供参考。
- EZH2等GCB相关突变提示靶向治疗(如EZH2抑制剂)的潜在价值。
局限性
- 回顾性研究设计。
- 样本量有限(原发骨DLBCL 34例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma subtype. This retrospective study elucidates the currently unknown genetic background of a large clinically well-annotated cohort of DLBCL with osseous localizations (O-DLBCL), including PB-DLBCL. A total of 103 patients with O-DLBCL were included and compared with 63 (extra)nodal non-osseous (NO)-DLBCLs with germinal center B-cell phenotype (NO-DLBCL-GCB). Cell-of-origin was determined by immunohistochemistry and gene-expression profiling (GEP) using (extended)-NanoString/Lymph2Cx analysis. Mutational profiles were identified with targeted next-generation deep sequencing, including 52 B-cell lymphoma-relevant genes. O-DLBCLs, including 34 PB-DLBCLs, were predominantly classified as GCB phenotype based on immunohistochemistry (74%) and NanoString analysis (88%). Unsupervised hierarchical clustering of an extended-NanoString/Lymph2Cx revealed significantly different GEP clusters for PB-DLBCL as opposed to NO-DLBCL-GCB (P < .001). Expression levels of 23 genes of 2 different targeted GEP panels indicated a centrocyte-like phenotype for PB-DLBCL, whereas NO-DLBCL-GCB exhibited a centroblast-like constitution. PB-DLBCL had significantly more frequent mutations in four GCB-associated genes (ie, B2M, EZH2, IRF8, TNFRSF14) compared with NO-DLBCL-GCB (P = .031, P = .010, P = .047, and P = .003, respectively). PB-DLBCL, with its corresponding specific mutational profile, was significantly associated with a superior survival compared with equivalent Ann Arbor limited-stage I/II NO-DLBCL-GCB (P = .016). This study is the first to show that PB-DLBCL is characterized by a GCB phenotype, with a centrocyte-like GEP pattern and a GCB-associated mutational profile (both involved in immune surveillance) and a favorable prognosis. These novel biology-associated features provide evidence that PB-DLBCL represents a distinct extranodal DLBCL entity, and its specific mutational landscape offers potential for targeted therapies (eg, EZH2 inhibitors).
引用
- de Groen RAL, van Eijk R, Böhringer S, et al. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Adv. 2021. PMID: 34478526. doi:10.1182/bloodadvances.2021005215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。